Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

RVX.TO Relative to the S&P 500

RVX.TO Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Resverlogix Corp. (TSE:RVX.TO) seasonal charts above shows that a Buy Date of October 25 and a Sell Date of January 24 has resulted in a geometric average return of 12.42% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 18 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 30.29% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

To download RVX.TO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: RVX.TO